Innovative therapeutics

RSS Feed

Investors

Press Releases

Email Alerts

Sep 15, 2020

BioMarin to Participate in Four Upcoming Virtual Investor Conferences

- J.P. Morgan U.S. All Stars Conference on September 16 at 11:00am ET/4:00BST

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in four upcoming virtual conferences. An audio webcast of the presentations will be available live. You...
Sep 11, 2020

BioMarin Announces Presentation of Vosoritide Phase 3 Data in Children with Achondroplasia at the American Society for Bone and Mineral Research 2020 Annual Meeting

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Lynda Polgreen, MD, MS, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA will present...
Sep 8, 2020

BioMarin Announces The Lancet Publishes Detailed Vosoritide Phase 3 Data Demonstrating Statistically Significant Increase in Annualized Growth Velocity (AGV) Over 52 Weeks in Children with Achondroplasia

Statistically Significant Increases in Height Z Score

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that The Lancet has published online results from a randomized, double-blind, phase 3, placebo-controlled, multicenter trial for...
Sep 8, 2020

BioMarin to Participate in Two Upcoming Virtual Investor Conferences

- Baird 2020 Global Healthcare Conference on September 9 at 11:25am ET

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences. An audio webcast of the presentations will be available live. You...
Aug 20, 2020

BioMarin Submits New Drug Application to U.S. Food and Drug Administration for Vosoritide to Treat Children with Achondroplasia

Potential first treatment for achondroplasia in the United States

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vosoritide, an investigational,...